Therapeutic Application of Iodine-131 Labelled Monoclonal Anti-CEA/CA 19-9, and OC 125 Antibodies

  • R. P. Baum
  • G. Hör
Conference paper

Abstract

The therapeutic use of iodine-131 for well differentiated thyroid carcinoma and benign diseases of the thyroid gland has been successfully applied since the early days of nuclear medicine and can be said by now to have stood the test of time. Other treatment modalities using radionuclides, however, such as phosphorus-32 (polycythaemia vera) and yttrium-90 (radiation synovectomy) among others, have not maintained their initial promise and have been partly replaced by nonradioactive therapeutics or advanced techniques in surgical management (Britton 1985).

Keywords

Lymphoma Fractionation Oncol Radionuclide Iodide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andres RY, Blattman H, Pfeiffer G et al. (1986) Radionuclides for therapy: a review. In: Schubiger RA, Hasler RH (eds) Radionuclides for therapy. Editiones Roche, Basle, pp 9–20Google Scholar
  2. Bale WF, Spar L, Goodland RL (1960) Experimental radiation therapy of tumor with I-131-carrying antibodies to fibrin. Cancer Res 20:1488PubMedGoogle Scholar
  3. Baum RP, Maul FD, Klapdor R et al. (1985) Immunszintigraphie kolorektaler Tumoren mit 131I-markierten monoklonalen Antikörpern (19-9/anti-CEA): erste Ergebnisse. Nuc Compact 16:121–128Google Scholar
  4. Baum RP, Maul FD, Senekowitsch R et al. (1986a) Radioimmunoscintigraphy of CA 19–9/CEA producing tumors using 131–I labelled F(ab′)2 fragments of monoclonal antibodies (19-9/anti-CEA radioimmunococktail). In: Winkler W (ed) Nuclear medicine in clinical oncology. Springer, Berlin Heidelberg New York, pp 197–206CrossRefGoogle Scholar
  5. Baum RP, Maul FD, Senekowitsch R et al. (1986b) Radioimmunoscintigraphy and radioimmunotherapy with monoclonal antibodies (19-9/anti-CEA and OC 125). In: Höfer R, Bergmann H (eds) Radioaktive Isotope in Klinik und Forschung, vol 17, part 1. Egermann, WienGoogle Scholar
  6. Baum RP, Chatal JF, Saccavini JC et al. (1986c) Radioimmunotherapy with 131I-labelled monoclonal antibodies 19-9/anti-CEA and OC 125. J Nucl Med 6:1019Google Scholar
  7. Baum RP, Lorenz M, Senekowitsch R et al. (1987a) Clinical experience in cancer diagnosis with radiolabeled monoclonal antibodies in 200 patients and initial attempts at radioimmunotherapy. In: Srivastava SC (ed) Radiolabeled monoclonal antibodies for imaging and therapy: potential, problems and prospects. Pergamon, New YorkGoogle Scholar
  8. Baum RP, Lorenz M, Senekowitsch R, Albrecht M, Hör G (1987b) Klinische Ergebnisse der Immunszintigraphie und Radioimmuntherapie. Nucl Med 26:68–78Google Scholar
  9. Beierwaltes WH (1956) Effects of some I-131 tagged antibodies in human melanoblas-toma: preliminary report. Univ Mich Med Bull 20:284–286Google Scholar
  10. Britton KE (1985) Nuclear medicine: a therapeutic future. Nucl Med Commun 6:749–752PubMedCrossRefGoogle Scholar
  11. Carrasquillo JA, Krohn KA, Beaumier P et al. (1984) Diagnosis and therapy of solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep 68:317–328PubMedGoogle Scholar
  12. Chatal JF, Saccavini JC, Fumoleau P et al. (1984) Immunoscintigraphy of colon carcinoma. J Nucl Med 25:307–314PubMedGoogle Scholar
  13. Delaloye B, Bischof-Delaloye A, Volant JC et al. (1985) First approach to therapy of liver metastases in colorectal carcinoma by intrahepatically infused 131-I labelled monoclonal anti-CEA antibodies. Eur J Nucl Med 11:A37CrossRefGoogle Scholar
  14. De Nardo SJ, De Nardo GL, O’Grady LF et al. (1986) Radioimmunotherapy of patients with B cell lymphoma using I-131 Lym-1 Mab. J Nucl Med 27:903Google Scholar
  15. Epenetos AA (1987) Intraperitoneal therapy of ovarian cancer. In: Srivastava SC (ed) Radiolabelled monoclonal antibodies for imaging and therapy: potential, problems, and prospects. Pergamon, New YorkGoogle Scholar
  16. Esteban JM, Colcher D, Sugarbaker P et al. (1987) Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B 72.3. Int J Cancer 39:50–59PubMedCrossRefGoogle Scholar
  17. Goldman A, Vivian G, Gordan I (1984) Immunolocalisation of neuroblastoma using radiolabelled monoclonal antibody UJ13A. J Pediat 105:252–256PubMedCrossRefGoogle Scholar
  18. Happ J, Baum RP, Griese J et al.(1986) Avidity of neuroadrenergic tumors for I-131-metaiodobenzylguanidine (I-131-MIBG) after the administration of diagnostic and therapeutic doses of I-131-MIBG. In: Schubiger RA, Hasler PH (eds) Radionuclides for therapy. Editiones Roche, Basle, pp 201–214Google Scholar
  19. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495PubMedCrossRefGoogle Scholar
  20. Larson SM, Carrasquillo JA, McGuffin RW et al. (1985) Use of 131-I labeled immune Fab against high molecular weight antigen of human melanoma: preliminary experience. Radiology 155:487–492PubMedGoogle Scholar
  21. Larson SM (1986) Diagnosis and treatment of metastatic tumors with radiolabeled monoclonal antibodies: experience with lymphoma, melanoma, and colon cancer. In: Srivastava SC (ed) Radiolabeled monoclonal antibodies for imaging and therapy: potential, problems, and prospects. NATO ASI Series, book of abstracts, Castelvec-chio Pascoli, Italy, p 27Google Scholar
  22. Lorenz M, Baum RP, Herrmann G et al. (1987) Immunohistochemistry and correlation with plasma levels of CA 19-9 and CEA in gastrointestinal tumors. In: Srivastava SC (ed) Radiolabeled monoclonal antibodies for imaging and therapy: potential, problems, and prospects. Pergamon, New YorkGoogle Scholar
  23. Mach JP, Chatal JF, Lumbroso JD et al. (1983) Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res 43:5593–5600PubMedGoogle Scholar
  24. Myers MJ (1986) Quantitative imaging and internal radiation dosimetry in the therapeutic use of labeled monoclonal antibodies. In: Srivastava SC (ed) Radiolabeled monoclonal antibodies for imaging and therapy: potential, problems, and prospects. NATO ASI Series, book of abstracts, Castelvecchio Pascoli, Italy, p 71Google Scholar
  25. Order SE, Klein JL, Ettinger DS et al. (1980a) Phase I-II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies. Int J Radiat Oncol Biol Phys 6:703–710PubMedCrossRefGoogle Scholar
  26. Order SE, Klein JL, Ettinger DS et al. (1980b) Use of isotopic immunoglobulin in therapy. Cancer Res 40:3001–3007PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • R. P. Baum
  • G. Hör

There are no affiliations available

Personalised recommendations